19
Jun
2015
Like the TR? Tell a Friend to Subscribe, and Enter to Win a T-Shirt
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jun
2015
Who’s Exploring DNA ‘Dark Matter’ for Drug Discovery?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2015
It’s Time to Re-Think Some Assumptions About Cancer R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jun
2015
NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2015
Bristol-Myers Should Drop the Bully Act. Non-Competes Are Bad for Biotech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jun
2015
Cancer is Hot, Diabetes is Not: Watch for Drug Safety and Cost Debates at ADA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jun
2015
Big Pharma Talent Is Flocking to Biotech Startups. Nobody’s Saying ‘Are You Nuts?’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
May
2015
Cancer Immunotherapy’s Amazing Four-Year Run: A Timeline of Events
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
May
2015
Long-Term Relationships May Not Count in Many Businesses, But They Do in Biotech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2015
The Genentech Alumni: Where Are They Now?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
May
2015
Why a Pfizer R&D Exec Joined Synlogic to Make ‘Therapeutic Synthetic Life’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
May
2015
Zigging Away From the Herd: Lilly’s Road-Less-Traveled R&D Strategy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2015
More than Moderna: Who’s Who in mRNA Therapeutics?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
May
2015
How Do VCs Divvy Up Their Pay?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
May
2015
Gates Foundation VC Portfolio: Where is the Global Health Investment Going?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2015
What’s Real, and What’s Not Yet, in Digital Health?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2015
Q&A With Illumina CEO Jay Flatley on Where Genomics Is Growing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2015
It’s Time to Re-Think How We Train and Develop Biomedical Scientists
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Apr
2015
See the Photos: Timmerman Report East Coast Launch Party
About nine months ago, I booked plane tickets for the whole family to go to Boston. The plan was to run the Boston Marathon, and maybe do a little sight-seeing. I didn’t realize at the time it would turn into a business trip. Oh, but it did, and what a great business-and-pleasure trip it was. After Timmerman Report went live... Read More
20
Apr
2015
Hungry for Cash, Academia Reaches For a Bigger Piece of Biotech Action
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.